Journal Watch · Frontiers in Immunology · 2026

Case Report: Hemophagocytic lymphohistiocytosis masquerading as drug-induced liver injury: successful treatment with low-dose ruxolitinib and glucocorticoids.

Early recognition and timely immunomodulatory therapy may improve outcomes in this life-threatening but treatable condition.

Dai Y, Zhang L, Zhong X et al.Frontiers in Immunology3 min readPharma relevance 65/100

DOI: 10.3389/fimmu.2026.1856139PMID: 42292459Study type: cohort / observational clinical study

TL;DR

Early recognition and timely immunomodulatory therapy may improve outcomes in this life-threatening but treatable condition.

Key findings

  • Genetic testing revealed heterozygous variants in immune-regulatory genes (NLRP3, DOCK8, MYO5A, PLCG2) classified as variants of uncertain significance, suggesting a potential predisposing role.
  • No significant adverse events related to ruxolitinib were observed.<h4>Conclusions</h4>HLH can initially present as severe DILI, posing diagnostic challenges.
  • Short-course, low-dose ruxolitinib combined with corticosteroids is a safe and effective treatment in patients with hepatic-predominant HLH.
  • Early recognition and timely immunomodulatory therapy may improve outcomes in this life-threatening but treatable condition.

What they did

Low-dose ruxolitinib plus corticosteroids were administered. Laboratory, imaging, genetic, and histopathological data were reviewed.<h4>Results</h4>All patients responded rapidly to the combination therapy, with progressive normalization of bilirubin and inflammatory markers. Transient declines in blood counts occurred but resolved without intervention.

Full abstract (original)

Background: <h4>Background</h4>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that can present with drug-induced liver injury (DILI), often mimicking acute liver failure and delaying diagnosis. Therapeutic options are limited in patients with severe hepatic dysfunction.<h4>Objectives</h4>To describe the clinical features, treatment, and outcomes of three adult patients presenting with DILI-mimicking HLH and evaluate the effectiveness of low-dose ruxolitinib combined with corticosteroids.<h4>Methods</h4>Three patients with DILI-like hepatic injury and secondary HLH were retrospectively analyzed. All patients exhibited severe hyperbilirubinemia and cytopenias refractory to conventional supportive therapy.

What they did: Low-dose ruxolitinib plus corticosteroids were administered. Laboratory, imaging, genetic, and histopathological data were reviewed.<h4>Results</h4>All patients responded rapidly to the combination therapy, with progressive normalization of bilirubin and inflammatory markers. Transient declines in blood counts occurred but resolved without intervention.

Results & conclusions: Genetic testing revealed heterozygous variants in immune-regulatory genes (NLRP3, DOCK8, MYO5A, PLCG2) classified as variants of uncertain significance, suggesting a potential predisposing role. No significant adverse events related to ruxolitinib were observed.<h4>Conclusions</h4>HLH can initially present as severe DILI, posing diagnostic challenges. Short-course, low-dose ruxolitinib combined with corticosteroids is a safe and effective treatment in patients with hepatic-predominant HLH. Early recognition and timely immunomodulatory therapy may improve outcomes in this life-threatening but treatable condition.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1856139 · PubMed 42292459.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

Early recognition and timely immunomodulatory therapy may improve outcomes in this life-threatening but treatable condition.

What type of study is this?

It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Low-dose ruxolitinib plus corticosteroids were administered.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1856139. PubMed ID: 42292459. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Dai Y, Zhang L, Zhong X et al.. Case Report: Hemophagocytic lymphohistiocytosis masquerading as drug-induced liver injury: successful treatment with low-dose ruxolitinib and glucocorticoids.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1856139.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/case-report-hemophagocytic-lymphohistiocytosis-masquerading-as-drug-indu-856139/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides